2 studies found for:    18809613 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NYESO-1 Murine TCR-Gene Engineered Lymphocytes
Conditions: Metastatic Cancers Other Than Melanoma That Express ESO Antigen;   Synovial Sarcoma;   Esophageal;   Heaptoma;   Breast;   Malignant Menigioma
Interventions: Genetic: Anti-NY ESO-1 mTCR PBL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
2 Terminated Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Conditions: Metastatic Cancer;   Metastatic Melanoma;   Metastatic Renal Cancer
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Other: IL-12 & amp; Anti-NY ESO1 TCR PBL

Indicates status has not been verified in more than two years